Drugs / PG201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03876210 | Jul 2019 | arthritic joint disease | PMG Pharm Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01576419 | Jan 2010 → Mar 2011 | osteoarthritis, knee | PMG Pharm Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG201 | “PK101, a fixed-dose combination (FDC) comprising PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine, and celecoxib, a selective cyclooxygenase-2 inhibitor” PMID 39560548 ↗ Nov 2024 |
| Modality | Traditional medicine (herbal / TCM) | “PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine” PMID 39560548 ↗ Nov 2024 |